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Homocysteine, renal function, and risk of cardiovascular disease. observed associations are likely to be causal; and to ex-
Background. Patients with renal impairment have markedly amine the importance of renal function as a determinant
elevated homocysteine levels and are at particularly high risk of homocysteine levels in healthy individuals.of ischemic heart disease (IHD) and stroke, but the relevance
of elevated homocysteine levels in this population is uncertain.
Methods. We examined the association with IHD from a
HOMOCYSTEINE AND RISK OF IHD ANDmeta-analysis of 30 population studies of differences in homo-
STROKE IN THE GENERAL POPULATIONcysteine concentrations (involving 5000 IHD and 1100 stroke
events in apparently healthy individuals), and from a meta- The initial epidemiologic evidence relating homocys-
analysis of 40 studies (involving 11,000 IHD events) of the associ- teine levels to risk of IHD or stroke in the general popu-ation of methylene-tetrahydrofolate reductase (MTHFR) and
lation came from retrospective case-control studies,homocysteine with IHD. We explored the association of renal
which reported that cases with IHD or stroke had higherfunction with homocysteine levels in a cross-sectional study of
1200 healthy elderly individuals. homocysteine levels than age-matched controls [1–3].
Results. Among prospective studies, a 25% lower blood More recently, however, apparently inconsistent results
homocysteine level was associated with an 11% lower risk of
for IHD have been reported from prospective cohort orIHD and about a 20% lower risk of stroke, after adjustment
nested case-control studies, with some showing highlyfor known cardiovascular risk factors. Individuals who had the
TT genotype for MTHFR compared with those with CC had significant results and others showing none [4]. Homo-
25% higher homocysteine levels and a 16% higher risk of IHD. cysteine levels are higher in current smokers than in
Among individuals aged over 65 years, a 1% higher serum nonsmokers and increase with increasing levels of sys-creatinine level was associated with about a 1% higher homo-
tolic blood pressure, serum total cholesterol, and serumcysteine concentration.
creatinine. It has been suggested that moderate eleva-Conclusions. The concordance of the IHD risks obtained in
the studies of genetically determined differences in homocys- tions of homocysteine in the general population may be
teine and the population-based studies of homocysteine suggest a consequence of atherosclerosis [10, 11] or of early
that these associations are likely to be causal. Renal function
“subclinical” renal impairment [11, 12].is an important determinant of circulating homocysteine con-
The initial meta-analysis of the observational studiescentrations. Results of ongoing randomized trials of folic acid-
based vitamins in patients with renal disease are required to of homocysteine and risk of vascular disease, published
clarify the relevance of lowering homocysteine for vascular in 1995, was based mainly on the results of retrospective
disease. studies and reported that a 5 mol/L increase in homo-
cysteine levels was associated with a 70% higher risk of
IHD and an 80% increased risk of stroke [3]. Conflicting
It has been suggested that total elevated blood homo- evidence has emerged recently from prospective studies,
cysteine concentrations are associated with an increased with some showing strong associations and others show-
risk of ischemic heart disease (IHD) and stroke [1–4]. ing none [4]. In order to assess the strength of the associa-
Although patients with renal impairment have markedly
tion between homocysteine and risk of cardiovascular
elevated homocysteine levels [5–8] and are at particularly
disease [13], the Homocysteine Studies Collaborationhigh risk of cardiovascular disease [9], the clinical rele-
(HSC) collected individual participant data from all thevance of elevated homocysteine levels in this population
observational studies of homocysteine and risk of IHDis uncertain.
and stroke. Table 1 shows the risks of IHD and of strokeThe aims of this review are to examine the epidemio-
for differences in homocysteine levels after classifyinglogic importance of elevated homocysteine levels for risk
studies by their design. Stronger associations were ob-of IHD and stroke; to assess the extent to which the
served in retrospective studies than in prospective stud-
ies, which excluded individuals with a history of a cardio-
Key words: homocysteine, heart disease, stroke, kidney function. vascular event at the time of blood collection (Table 1).
The results of these prospective studies are less prone 2003 by the International Society of Nephrology
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Table 1. Odds ratio and 95% confidence interval (CI) of ischemic heart disease and stroke for a 25% lower usual homocysteine
after adjustment for age, sex, and study
Study design No. of events Heart disease No. of events Stroke
Prospective:
No vascular disease at baseline 1968 0.83 (0.77–0.89) 463 0.77 (0.66–0.90)
Retrospective:
Population controls 2496 0.67 (0.62–0.71) 344 0.86 (0.73–1.01)
Retrospective:
Other controls 609 0.73 (0.64–0.83) 306 0.46 (0.30–0.70)
Table 2. Odds ratio and 95% confidence interval (CI) of ischemic
heart disease and stroke in prospective studies for a 25%
lower usual homocysteine, after adjustment for known
cardiovascular risk factors
Heart disease Stroke
With adjustment for (N  1855) (N  435)
Age and sex 0.83 (0.77–0.90) 0.77 (0.66–0.90)
Age, sex, & smoking 0.85 (0.78–0.91) 0.78 (0.67–0.91)
Age, sex, smoking, & systolic
blood pressure 0.89 (0.82–0.96) 0.81 (0.69–0.96)
Age, sex, smoking, systolic blood
pressure, & total cholesterol 0.89 (0.83–0.96) 0.81 (0.69–0.95)
to the influence of preexisting cardiovascular disease on
Fig. 1. Distribution of mean homocysteine levels according to fifths ofhomocysteine levels (“reverse causality”). Consequently,
serum creatinine levels in the Oxford Healthy Aging Project. Individu-the chief emphasis in the HSC meta-analysis was on als were classified into younger (aged 65–74 years) or older (75 years
the results of prospective studies of apparently healthy or greater) members of the population.
populations. Table 2 shows the risks of IHD and stroke
associated with differences in homocysteine concentra-
tions in prospective studies after adjustment for the ef- [15] in order to assess the true strength of the association
of the TT genotype for MTHFR and risk of IHD. Datafects of known cardiovascular risk factors. After adjust-
ment for age, sex, study, systolic blood pressure, and were obtained from 40 studies, involving a total of about
11,000 cases and 13,000 controls. Individuals with the TTtotal cholesterol, a 25% lowering in usual homocysteine
levels (about 3 mol/L) was associated with an 11% polymorphism not only had a 25% higher homocysteine
level, but also had a 16% higher risk (95% CI, 5% to(95% CI, 4% to 17%) lower risk of IHD, and a 19%
(95% CI, 5% to 31%) lower risk of stroke. Thus, the 28%) of IHD. The net effect of the MTHFR polymor-
phism is attenuated when folate levels are replete. Stud-evidence from population studies of homocysteine dif-
ferences suggests that elevated homocysteine is an inde- ies of genetically-determined differences in homocys-
teine are free from the possibility of reverse causality,pendent, albeit modest, risk factor for cardiovascular
disease. and therefore provide strong support for the association
between homocysteine levels and cardiovascular disease
being causal.
EVIDENCE THAT THE OBSERVED
ASSOCIATION IS LIKELY TO BE CAUSAL
RENAL FUNCTION AS A DETERMINANTStudies of genetic variants affecting homocysteine lev-
OF HOMOCYSTEINE LEVELS INels and risk of heart disease could help to provide evi-
HEALTHY INDIVIDUALSdence about the causal nature of these underlying associ-
ations [14]. Among the genetic variants associated with Homocysteine levels are elevated 2- to 3-fold among
patients with renal disease [5–8]. Circulating homocys-homocysteine levels, the C677T polymorphism for the
gene-encoding MTHFR is the most important [14]. Indi- teine concentration increases in a graded manner, with
decreasing levels of renal function, not only among pa-viduals who have a C to T substitution at base 677 in
both copies of the gene that encodes MTHFR (TT homo- tients with established renal failure [5–8], but also in
those with normal [16, 17] or supra-normal [18] glomeru-zygotes) have about 2.5 mol/L higher homocysteine
levels than those with the CC genotype. The MTHFR lar filtration rates (GFR). Figure 1 shows mean homocys-
teine levels for fifths of creatinine among 1200 individualscollaboration collected individual participant data from
all the observational studies of MTHFR and risk of IHD in the Oxford Healthy Aging Project, separately for indi-
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